Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
| Autor: | Jamal Tarazi, Subramanian Hariharan, Thomas E. Hutson, M. Dror Michaelson, Laura Cisar, Angel H. Bair, Yoshihiko Tomita, Brad Rosbrook, Mayer Fishman, Brian I. Rini, Eric Jonasch, Victor Gruenwald |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty Indazoles Axitinib First line Urology Antineoplastic Agents Receptor Platelet-Derived Growth Factor beta Young Adult 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Carcinoma Humans Medicine Pharmacology (medical) In patient Carcinoma Renal Cell Survival analysis Aged Neoplasm Staging Retrospective Studies Aged 80 and over business.industry Imidazoles Retrospective cohort study Middle Aged medicine.disease Survival Analysis Kidney Neoplasms Tumor Burden Surgery Clinical trial Receptors Vascular Endothelial Growth Factor 030104 developmental biology Oncology 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | Targeted Oncology. 12:333-340 |
| ISSN: | 1776-260X 1776-2596 |
| DOI: | 10.1007/s11523-017-0487-4 |
| Popis: | We conducted a retrospective analysis of two clinical trials in treatment-naïve patients (n = 402) with advanced renal cell carcinoma (RCC) treated with axitinib. Our objective was to compare duration of treatment (DT) and clinical outcome in patients who achieved DT18 months (longer DT) versus ≤18 months (shorter DT).DT, objective response rate (ORR), tumor shrinkage, and overall survival (OS) were summarized for patients with longer and shorter DT.Overall, 152 patients (37.8%) had longer DT and 250 (62.2%) had shorter DT (median, 34.7 vs. 6.5 months, respectively). ORR in all 402 patients with advanced RCC was 43.5%. ORR was 75% for longer DT versus 24.4% for shorter DT (p 0.0001). More patients with longer DT versus shorter DT had ≥10% tumor shrinkage at first scan (74.8% vs. 55.3%; p = 0.0001) and maximum on-study tumor shrinkage was greater in longer-DT versus shorter-DT group (-51.8% vs. -22.1%; p 0.0001). Median OS was 32.6 months in the overall population while in the patients with longer DT the median was not reached. Treatment-related adverse events (AEs) grade ≥3 were more frequent in longer-DT versus shorter-DT and included hypertension (25.7% vs. 18.8%), diarrhea (15.1% vs. 4.4%), and weight decrease (11.2% vs. 3.2%); however, these AEs decreased over time in both groups. Eastern Cooperative Oncology Group performance status 0, favorable hematology values, no bone or liver metastases, and baseline tumor burden below the overall median were associated with longer DT.Longer duration (18 months) of axitinib treatment was associated with increased frequency of early tumor shrinkage, greater magnitude of tumor shrinkage, and a favorable OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink